Abstract Titles
Skip to Late-Breaking Abstracts »
All accepted abstracts will be available in the Journal for ImmunoTherapy of Cancer (JITC).
Abstract Titles
Onsite Posters
Onsite posters will be presented in the Poster Hall at the Walter E. Washington Convention Center in Washington, D.C. All odd numbered posters will be presented on Friday, Nov. 12, 2021. Even numbered posters will be presented Saturday, Nov. 13, 2021.
ePosters
ePosters will be on display on the SITC 2021 virtual meeting platform from 7 a.m. EST on Friday, Nov. 12, 2021 until the virtual meeting platform is closed on Jan. 9, 2022.
| # | Type | Title | Authors | Category | Keywords | |
|---|---|---|---|---|---|---|
| 552 | Poster Presentation | Amphiphile-peptide boosting with FMC63-binding surrogate peptide mimotopes induces activation and potent effector function in CAR-T cells targeting CD19 | Ana Castano, MD; Peter C. DeMuth, PhD; Amy Tavares | Combination Immunotherapies | CAR T cells;Dendritic cell;T cell | |
| 553 | Poster Presentation | First-in-class inhibitors of ERAP1 alter the immunopeptidome of cancer, driving a differentiated T cell response leading to tumor growth inhibition | Peter I. Joyce, PhD; Martin Quibell, PhD; Jason Shiers, PhD; Carmen Tong, PhD; Kristopher Clark, PhD; Nicola Ternette, PhD; Kate Anderton, BSc; Jessica Sette, BSc; Wayne Paes, PhD; Andrew J. Leishman, PhD | Combination Immunotherapies | Checkpoint blockade;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 554 | Poster Presentation | The panorama of tumor intrinsic immune regulators exhibited by genome-wide CRPISR immune screen integrated with comprehensive clinical dataset analysis | Jiakai Hou, Ph.D; Yunfei Wang; Leilei Shi, PhD; Yuan Chen; Chunyu Xu; Arash Saeedi; Ke Pan; Ritu Bohat; Nicholas A. Egan; Jodi A. McKenzie; Rina M. Mbofung; Leila Williams; Zhenhuang Yang; Ming Sun; Xiaofang Liang; Jordi Rodon Ahnert; Navin Varadarajan, PhD; Cassian Yee; Yiwen Chen; Patrick Hwu; Weiyi Peng, PhD | Combination Immunotherapies | Bioinformatics;Epigenetics;Systems biology;Tumor microenvironment | |
| 555 | Poster Presentation | A high-throughput in situ screen to identify synergistic combinations of immune-oncology drugs with targeted and cytotoxic agents in a patient-derived humanized mouse model of renal cancer | Oliver Jonas, PhD; Eva Oswald, PhD; Kanstantsin Lashuk; Sebastian Ahn, PhD; Julia Schuler, DVM PhD | Combination Immunotherapies | Antibody;Checkpoint blockade;Proteomics;Solid tumors;T cell;Tumor microenvironment | |
| 556 | Poster Presentation | Chemo-immunotherapy to treat bone-metastatic prostate cancer | Shreya Kumar, MS; Marxa L. Figueiredo, Ph.D. | Combination Immunotherapies | Chemotherapy;Cytokine;Solid tumors;Tumor microenvironment | |
| 557 | Poster Presentation | Neoadjuvant Camrelizumab in combination with albumin paclitaxel and cisplatin for patients with locally advanced esophageal squamous cell carcinoma (ESCC) | Huilai Lv; Yang Tian; Zhenhua Li; Chao Huang; Yanzhao Xu; Ziqiang Tian | Combination Immunotherapies | Antibody;Checkpoint blockade;Chemotherapy;Clinical study;Immune tolerance;Immune toxicity;Surgery;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 559 | Poster Presentation | Preclinical evaluation of pegylated liposomal Doxorubicin or Doxorubicin with mATRC-101 in the EMT6 syngeneic mouse model | Erin Wechsler, PhD; Nikhil Vad, PhD; Danhui Zhang, MD PhD | Combination Immunotherapies | Antibody;Chemotherapy;Costimulation;Solid tumors;Targeted therapy;Tumor antigens | |
| 560 | Poster Presentation | Immunotherapeutic and antimetastatic activity of LTX-315 in preclinical models of ICI-resistant breast cancer | Takahiro Yamazaki, PhD; Erik Wennerberg, PhD; Michal Hensler; Aitziber Buqué Martinez, PhD; Jeffrey Kraynak; Jitka Fucikova; Xi Zhou; Baldur Sveinbjornsson, PhD; Oystein Rekdal, PhD; Sandra Demaria, MD; Lorenzo Galluzzi, PhD | Combination Immunotherapies | Antigen presenting cells;Chemotherapy;Dendritic cell;NK/NKT cell;Radiotherapy;Solid tumors;Tumor infiltrating lymphocytes (TILs) | |
| 561 | Oral Presentation | Triple checkpoint blockade, but not anti-PD1 alone, enhances the efficacy of engineered adoptive T cell therapy in advanced ovarian cancer | Kristin G. Anderson, PhD; Yapeng Su; Madison G. Burnett; Breanna Bates, BS; Magdalia Rodgers Suarez; Susan L. Ruskin; Aesha Vakil; Valentin Voillet, PhD; Raphael Gottardo, PhD; Philip D. Greenberg, MD | Combination Immunotherapies | Checkpoint blockade;Immune suppression;Solid tumors;T cell;Tumor microenvironment | |
| 562 | Poster Presentation | Real-world assessment of current treatment patterns and clinical outcomes among patients with EGFR and ALK wild type non-small cell lung cancer (NSCLC) in the US | Lyudmila Bazhenova, MD; Jonathan K. Kish, PhD MPH; Beilei Cai; Nydia Caro; Bruce Feinberg | Combination Immunotherapies | Checkpoint blockade;Solid tumors | |
| 563 | Poster Presentation | ICT01, an anti-BTN3A mAb, and NL-201, an alpha-independent IL-2/IL-15 agonist, combine to elicit a potent anti-tumor response by synergistically stimulating Vg9Vd2 T cell activation and proliferation | Aude De Gassart, PhD; Patrick Brune; Maelle Mairesse; Sophie Agaugué; Ryan Swanson, BS; Loui Madakamutil; Carl Walkey; Paul A. Frohna, MD, PhD, PharmD; Aude de Gassart, PhD | Combination Immunotherapies | Antibody;Cytokine;T cell | |
| 564 | Poster Presentation | Single-cell transcriptomic analysis of immune compartments following combination immunotherapy treatment in poorly immunogenic tumors | Ang Cui, PhD; Kelly D. Moynihan, PhD; Shuqiang Li, PhD; Chensu Wang, PhD; Jackson Southard; Nir Hacohen, PhD; Darrell J. Irvine, Ph.D. | Combination Immunotherapies | Bioinformatics;Solid tumors;Systems biology;Tumor microenvironment | |
| 565 | Poster Presentation | Combinatorial HSCs and anti-PD-1 therapy in microsatellite stable colorectal cancer | Bayli DiVita Dean, PhD; John Figg; Laura Falceto Font, BS; Connor Francis; Duane Mitchell; Catherine Flores | Combination Immunotherapies | Checkpoint blockade;Dendritic cell;Solid tumors | |
| 566 | Poster Presentation | ATOR-1017, a second generation 4-1BB antibody with potential to enhance efficacy of PD-1 therapies | Karin Enell Smith, PhD, MS; Anneli Nilsson; Peter Ellmark, PhD | Combination Immunotherapies | Antibody;Costimulation;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 567 | Poster Presentation | Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of stroma poor cancers | Sadna Budhu, PhD; Aditi Gupta, MD; Kelly J. Fitzgerald, MD/PhD; Rachel A. Giese, MD; Adam O. Michel, DVM, MVSc, Dr.med.vet., DACVP; Aliya Holland; Luis Felipe F. Campesato, PhD, MS; Jacques Van Snick, PhD; Catherine Uyttenhove, PhD; Gerd Ritter, PhD; Jedd D. Wolchok, MD/PhD; Taha Merghoub, PhD | Combination Immunotherapies | Checkpoint blockade;Cytokine;Immune suppression;Tumor microenvironment | |
| 568 | Poster Presentation | Tumor-derived GDF-15 prevents therapy success of checkpoint inhibitors by blocking T-lymphocyte recruitment | Markus Haake, PhD; Tina Schäfer, PhD; Beatrice Haack; Neha Vashist, PhD; Sabrina Genßler, PhD; Patrick Harter, MD; Alexander Martens, PhD; Kilian Wistuba-Hamprecht, PhD; Florian Wedekink; Birgitt Fischer; Michel Mittelbronn, MD; Mitchell Levesque, PhD; Phil Cheng, PhD; Reinhard Dummer, MD; Benjamin Weide, MD; Kathrin Klar, PhD; Eugen Leo, MD, PhD, MBA; Falk Nimmerjahn, PhD; Christine Schuberth-Wagner, PhD; Jörg Wischhusen, PhD | Combination Immunotherapies | Antibody;Checkpoint blockade;Cytokine;Immune suppression;Immune tolerance;Solid tumors;T cell lineages;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 569 | Poster Presentation | A novel microbiome-derived peptide reverses resistance to anti-PD-1 therapy | Dhwani D. Haria, MS; Jayamary Divya Ravichandar; Jill Desnoyer; Sabina Lau; Jina Lee; Erica Rutherford; Preeti Lal; Karim Dabbagh; Helena Kiefel, PhD | Combination Immunotherapies | Antigen presenting cells;Checkpoint blockade;Chemokine;Cytokine;Dendritic cell;Microbiome;Myeloid cells;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 570 | Poster Presentation | Blockade of the inhibitory collagen receptor LAIR-1, PD-L1, and TGF-β promotes anti-tumor activity through T cell activation and myeloid cell polarization | Lucas A. Horn, PhD; Haiyan Qin; Kristen N. Fousek, PhD; Masafumi Iida, MD, PhD; Dallas B. Flies, PhD; Ronald Copeland; Zachary Cusumano, Ph.D.; Han Myint; Solomon Langermann; Jeffrey Schlom, PhD; Claudia M. Palena, PhD | Combination Immunotherapies | Monocyte/Macrophage;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 571 | Poster Presentation | IL-2 combination with ImmTAC overcomes CD163+ TAM-like M2 macrophage inhibition of ImmTAC-mediated T cell killing of tumor cells | Rahul Khanolkar; Revashnee Naidoo; Esra Güç; Emma Leach; Sarah Stanhope; Duncan Gascoyne; Laura Collins; Koustubh Ranade; Adel Benlahrech | Combination Immunotherapies | Cytokine;Immune suppression;Monocyte/Macrophage;T cell;Tumor microenvironment | |
| 572 | Poster Presentation | Combination therapy of exoSTING, exoIL-12 activates systemic anti-tumor immunity | Katherine Kirwin; Su Chul Jang, PhD; Christine Sia; Kevin Dooley; Tong Zi; Kelvin Zhang, PhD; Yanyan Liu, PhD; Kyriakos Economides, PhD; Shil Patel, PhD; Sriram Sathyanaryanan, PhD | Combination Immunotherapies | Checkpoint blockade;Extracellular vesicles/exosomes;T cell | |
| 573 | Poster Presentation | FS120, an OX40/CD137 tetravalent bispecific dual agonist antibody, synergistically increases the antitumor activity of anti-PD-1 in preclinical studies | Matthew A. Lakins, PhD; Wenjia Liao; Emma McConnell; Quincy Kaka; Jennifer Ofoedu; Cristian Gradinaru; Raffaella Giambalvo; Miguel Gaspar; Edmund Poon; Michelle Morrow, PhD; Neil Brewis | Combination Immunotherapies | Antibody;Bispecifics;Checkpoint blockade;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 574 | Poster Presentation | Multiplex microscopy reveals unique spatiotemporal effects of cancer immunotherapies | Vivien I. Maltez, PhD; Katelyn Byrne, PhD; Ronald N. Germain, MD, PhD | Combination Immunotherapies | Checkpoint blockade;Dendritic cell;Regulatory T cell (Treg cell);Solid tumors;Systems biology;T cell;T cell lineages;Tumor microenvironment | |
| 575 | Poster Presentation | Dual blockade of LAG3 and TIGIT improves the treatment efficacy of a nanoparticle-mediated immunoradiation in anti-PD1 resistant lung cancer in mice | Yun Hu, PhD; James Welsh; Sebastien Paris; Genevieve Bertolet; Hampartsoum Barsoumian; Lily Schuda; Kewen He; Duygu Sezen; Mark Wasley; Joylise Mitchell; Tiffany Voss; Fatemeh Masrorpour; Jordan SILVA; Claudia Kettlun Leyton; Liangpeng Yang; Nahum Puebla-Osorio; Saumil Gandhi; Quynh-Nhu Nguyen; Angelica Cortez | Combination Immunotherapies | Antibody;Radiotherapy;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine | |
| 576 | Poster Presentation | Tumor Targeted Superantigen (TTS), Naptumomab Estafenatox (NAP), enhances CAR-T cells potency and can boost CAR-T efficacy against solid tumors | yael Sagi, PhD; Michal Shahar, PhD; Marina Pinsker, MSc | Combination Immunotherapies | Adoptive immunotherapy;CAR T cells;Solid tumors;T cell;Tumor microenvironment | |
| 577 | Poster Presentation | Non-clinical efficacy, pharmacokinetics, and pharmacodynamics of a novel bi-functional anti-CD73-TGFβRII-trap molecule in combination with immune checkpoint therapy | Susanna Y. Stinson, MS; Jianhua He; Kyung-Hoon Kim; Becky Yang; Marianna Zavodovskaya, M.S.; Ping Yi; Federico Campigotto; Monika Sobczyk; Rutwij Dave; Brian Carr; In Kyoung Mah; Shiva Zaboli; Jens Brodbeck; Scott Turner; Vivian Barry; Kelli Boyd; Valeria Fantin | Combination Immunotherapies | Immune suppression;Tumor microenvironment | |
| 578 | Oral Presentation | CD8-targeted IL-2 drives potent anti-tumor efficacy and promotes action of tumor specific vaccines | Hussein Sultan, Ph.D.; Kelly D. Moynihan, Ph.D.; Yuang Song, B.A.; Samuel Ameh, B.A.; Ton N. Schumacher, PhD; Yik Andy Yeung, Ph.D.; Ivana Djuretic, Ph.D.; Robert D. Schreiber, PhD | Combination Immunotherapies | Checkpoint blockade;Cytokine;Immune adjuvant;Neoantigens;T cell;Tumor antigens;Vaccine | |
| 579 | Poster Presentation | Exploiting tumor neoantigen-targeted immunotherapy in immunologically hot versus cold murine lung cancer models | Changbo Sun, MD; Koji Nagaoka, PhD; Yukari Kobayashi, BS; Jun Nakajima, MD, PhD; Kazuhiro Kakimi, MD, PhD | Combination Immunotherapies | Adoptive immunotherapy;Checkpoint blockade;Immune suppression;Neoantigens;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor microenvironment;Vaccine | |
| 580 | Poster Presentation | Glutamine blockade in combination with immune checkpoint blockade remodels the myeloid landscape in mouse models of soft tissue sarcomas | Aditya A. Suru, BTech; Marwa Islam; Ada Tam; Dr. John Gross, MD; Nicolas J. Llosa, MD | Combination Immunotherapies | Checkpoint blockade;Immune suppression;MDSC;Metabolism;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy;Tumor microenvironment | |
| 581 | Poster Presentation | Multi-dimensional Synergy of Combinations (MuSYC) Algorithm Optimizes Combinatorial STING and TLR Adjuvant Cancer Vaccines | David R. Taylor, B.S. in Chemistry; Michael J. Korrer, PhD | Combination Immunotherapies | Antigen presenting cells;Costimulation;Dendritic cell;Immune adjuvant;Myeloid cells;T cell;TLR;Tumor antigens;Tumor microenvironment;Vaccine | |
| 582 | Poster Presentation | Immune correlates from QuEST1 in men with castration-resistant prostate cancer | Nicole J. Toney, Ph.D; Yo-Ting Tsai, PhD; Jason M. Redman, MD; James L. Gulley, MD, PhD; Jeffrey Schlom, PhD; Renee N. Donahue, PhD | Combination Immunotherapies | Checkpoint blockade;Clinical study;Clinical trial;Immune monitoring;NK/NKT cell;Proteomics;Solid tumors;T cell;Tumor antigens;Vaccine | |
| 583 | Poster Presentation | Exploring the Potential of T Cell Acute Lymphoblastic Leukemia (T-ALL) for Generating Leukemia-Specific T cell Responses that can be Therapeutically Harnessed with Immunotherapy | Todd A. Triplett, PhD; Joshua F. Rios; Alexander Somma; Sarah E. Church, PhD; Khrystyna North; Andrew M. White, BSc; Nisha Holay, B.S.; Andrew D. Weinberg, PhD | Combination Immunotherapies | Checkpoint blockade;Immune contexture;Leukemia/Lymphoma;T cell;T cell lineages;Tumor microenvironment;Tumor stroma | |
| 584 | Poster Presentation | Powerful synergistic effects of a STING agonist and the IL-2 superkine, H9, in eliciting NK and T cell responses against MHC I- and MHC I+ tumors | Natalie K. Wolf, BS; Cristina Blaj, PhD; Lora Picton; Gail Snyder; Li Zhang; Christopher J. Nicolai; Chudi Ndubaku; Kelsey E. Sivick Gauthier; Sarah McWhirter, PhD; K. Christopher Garcia; David Raulet, PhD | Combination Immunotherapies | Checkpoint blockade;Cytokine;NK/NKT cell;T cell | |
| 585 | Poster Presentation | LIGHT (TNFSF14) co-stimulation enhances myeloid cell activation and anti-tumor immunity in the setting of PD-1 and TIGIT checkpoint blockade | George J. Fromm, Jr., Ph.D.; Kyung Jin Yoo; Kellsey Johannes; Casey Shuptrine; Zach Opheim; Arpita Patel; Haley Andreasen; Jaya Miriyala; Suresh De Silva, Ph.D.; Taylor H. Schreiber, MD, PhD | Combination Immunotherapies | Bispecifics;Checkpoint blockade;Costimulation;NK/NKT cell;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs) | |
| 586 | Poster Presentation | Monitoring the impact of MDSC targeting drugs in combination with nivolumab on activation and proliferation of tumor resident effector immune cells in patient-derived 3D-EXplore platform | Jared C. Ehrhart, PhD; Brittany Bunch; Kelly Sussman; Kelly Guzman; Soner Altiok, MD, PhD | Combination Immunotherapies | Checkpoint blockade;Costimulation;Immune suppression;MDSC;Solid tumors;Tumor evasion;Tumor microenvironment;Tumor stroma | |
| 587 | Poster Presentation | Inducing mismatch repair deficiency in combination with anti-CTLA4 therapy is highly effective against non-immunogenic neuroblastoma tumors | Mikal El-Hajjar, MSc; Lara Gerhardt, BSc; Mithunah Krishnamoorthy, PhD; Rene Figueredo, MSc; Xiufen Zheng, PhD; James Koropatnick, PhD; Saman Maleki, PhD | Combination Immunotherapies | Bioinformatics;Checkpoint blockade;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 588 | Poster Presentation | Caloric restriction sensitizes melanoma to anti-PD-1 immune checkpoint inhibition | Alexa D. Melucci, MD; Shuyang S. Qin, M.S; Alexander C. Chacon, MD; Rachel Jewell; Peter A. Prieto, MD, MPH | Combination Immunotherapies | Checkpoint blockade;Immune suppression;Inflammation;T cell | |
| 589 | Poster Presentation | Enhancement of the anti-tumor effects of CD47 blockade in solid tumors by combination with targeted radioimmunotherapy | Denis Beckford, PhD; Sagarika Pachhal; Emily Greer; Jesse Hwang; Qing Liang; Mary Chen; Eileen Geoghegan; Helen Kotanides; Dale Ludwig | Combination Immunotherapies | Antibody;Checkpoint blockade;Radiotherapy;Solid tumors;Targeted therapy | |
| 590 | Poster Presentation | Anti-CD33 actinium-225 targeted radioimmunotherapy enhances the biologic activity of anti-CD47 antibody immunotherapy in preclinical models of acute myeloid leukemia | Denis Beckford, PhD; Sagarika Pachhal; Emily Greer; Jesse Hwang; Qing Liang; Mary Chen; Eileen Geoghegan; Helen Kotanides; Dale Ludwig | Combination Immunotherapies | Antibody;Radiotherapy;Targeted therapy | |
| 591 | Poster Presentation | Survival rates in Stage IV melanoma patients treated with radiation and immunotherapy differ depending on age and radiation treatment site | Catherine Colonna, MS; Nasreen A. Vohra, MD; Aiden Burke, MD; Matthew S. Peach, MD; Andrew W. Ju, MD | Combination Immunotherapies | Checkpoint blockade;Radiotherapy | |
| 592 | Oral Presentation | ATR-mediated CD47 and PD-L1 upregulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer | Rodney Cheng-En Hsieh, MD; Sunil Krishnan; Ren-Chin Wu; Akash R. Boda, MS; Arthur J. Liu, BS; Michelle Winkler, BS; Wen-Hao Hsu; Steven H. Lin; Mien-Chie Hung; Li-Chuan Chan; Krithikaa R. Bhanu; Anupallavi Srinivasamani, MS; Ricardo A. De Azevedo; Yung-Chih Chou; Ronald Depinho; Matthew M. Gubin, PhD; Eduardo Vilar-Sanchez, MD, PhD; Chao-Hsien Chen; Ravaen Slay; Priyamvada Jayaprakash, PhD; Shweta M. Hegde; Genevieve P. Hartley, PhD; Spencer T. Lea, BA; Rishika Prasad, MS; Brittany Morrow; Coline A. Couillault, PhD; Madeline Steiner; Chun-Chieh Wang; Bhanu P. Venkatesulu; Cullen Taniguchi; Betty Y. Kim; Junjie Chen; Nils-Petter Rudqvist, PhD; Michael A. Curran, PhD | Combination Immunotherapies | Antigen presenting cells;Checkpoint blockade;Coinhibition;Immune suppression;Radiotherapy;T cell;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 593 | Poster Presentation | PI3Kγδ inhibitor combined with radiation enhances the antitumor immune effect of PD-1 blockade in syngenic murine breast cancer model and humanized patient-derived xenograft model | MIn Guk Han, PHD student; Bum Sup Jang, PHD; Mi Hyun Kang, MS; Deukchae Na, PhD; In Ah Kim, MD, PhD | Combination Immunotherapies | Checkpoint blockade;Immune tolerance;MDSC;Monocyte/Macrophage;Radiotherapy;Regulatory T cell (Treg cell);Tumor microenvironment | |
| 594 | Poster Presentation | Combination of antigen-specific vaccination and targeted radionuclide therapy improves anti-tumor efficacy in a murine prostate model | Hemanth K. Potluri, BA; Carolina A. Ferreira, PhD; Joseph Grudzinski, PhD; Christopher Massey; Reinier Hernandez, PhD; Jamey Weichert, PhD; Douglas G. McNeel, MD, PhD | Combination Immunotherapies | Dendritic cell;Radiotherapy;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine | |
| 595 | Poster Presentation | Inhibition of integrin αvβ8 in combination with low dose radiation induces antitumor effect in advanced immune checkpoint blockade refractory tumor model | Natalia J. Reszka-Blanco, PhD; Megan Krumpoch; Michaela Mentzer; Vinod Yadav Yadav; Brianna Bannister; Dan Cui; Elizabeth Konopka; Dooyoung Lee; Fu-Yang Lin; Terence I. Moy; Eugene Nebelitsky; Qi Qiao; Inese Smutske; Charlotte A. Root; Patrick Allison; Sarah A. Krueger; Dawn Troast; Blaise Lippa; Bruce N. Rogers; Adrian S. Ray | Combination Immunotherapies | Antigen presenting cells;Costimulation;Dendritic cell;Immune suppression;Immune tolerance;Radiotherapy;Solid tumors;Tumor evasion;Tumor infiltrating lymphocytes (TILs) | |
| 596 | Poster Presentation | Combining Bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) pairs local innate activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity | Annah S. Rolig, Ph. D; Daniel C. Rose, BS in biology; Grace Helen C. McGee; Saul Kivimae, PhD; Werner Rubas, PhD; William L. Redmond, Ph.D. | Combination Immunotherapies | Cytokine;Immune adjuvant;Radiotherapy;T cell;TLR;Tumor infiltrating lymphocytes (TILs) | |
| 597 | Poster Presentation | The role of CCL20 in mediating regulatory T cell infiltration and resistance to radiotherapy in head and neck squamous cell carcinoma | Cleopatra Rutihinda, BSc; Leanié Moreau, BSc; Safia Chelighem, BSc; Ayman J. Oweida, PhD | Combination Immunotherapies | Antibody;Chemokine;Cytokine;Radiotherapy;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 598 | Poster Presentation | Local radiation in combination with CpG and anti-OX40 induces enhanced T cell activation and proliferation | Dan Spiegelman, BS; Alexander Pieper, B.S.; Luke M. Zangl, BS; Arika S. Feils, BS; Anna Hoefges, MS; Mildred A. Felder, BS; Sritha Moram, BS; Alexander L. Rakhmilevich, MD, PhD; Amy K. Erbe, PhD; Jacquelyn A. Hank, PhD; Ravi Patel, MD, PhD; Zachary S. Morris, MD, PhD; Paul M. Sondel, MD, PhD | Combination Immunotherapies | Costimulation;Radiotherapy;T cell;Vaccine | |
| 599 | Poster Presentation | Cyclophosphamide augments the efficacy of an in situ vaccine in a mouse melanoma model | Noah Tsarovsky, BS; Mildred A. Felder, BS; Mackenzie Heck; Jacob Slowinski; Kayla Rasmussen; Sabrina VandenHeuvel; Zachary S. Morris, MD, PhD; Amy K. Erbe, PhD; Paul M. Sondel, MD, PhD; Alexander L. Rakhmilevich, MD, PhD | Combination Immunotherapies | Chemotherapy;Cytokine;Immune adjuvant;Radiotherapy;T cell;Vaccine | |
| 600 | Poster Presentation | BR101801 stimulates anti-tumor immunity and enhances the efficacy of radiation in a syngeneic model | Seungho Wang, MS; Yi Na Yoon; Mi kwon Son; Soo Jung Kim; Bo Ram Lee; Eun hee Yang; Byeongwook Jeon; Seung Hyun Lee; Tae-Jin Kim; Jae-Sung Kim; Joo Han Lee | Combination Immunotherapies | Immune adjuvant;MDSC;Myeloid cells;Radiotherapy;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 601 | Oral Presentation | Sequencing Immunotherapy Before Lymphatic Ablation Unleashes cDC1-Dependent Antitumor Immunity in HNSCC | Robert Saddawi-Konefka, MD PhD; Aoife E. O'Farrell, BS; Farhoud Faraji, MD PhD; Michael Allevato, BA; Zhiyong Wang, PhD; Victoria H. Wu, BA; Bryan S. Yung, MA; Nana-Ama A. Anang, BS; Ida Franiak-Pietryga, PhD; Aaron B. Simon, MD PhD; Shawn Jensen, PhD; Bernard A. Fox, PhD; Andrew Sharabi, MD, PhD, FACS; Ezra EW. Cohen, MD; Joseph Califano, MD; J. Silvio Gutkind | Combination Immunotherapies | Checkpoint blockade;Dendritic cell;Solid tumors;Surgery;Systems biology;Tumor evasion | |
| 602 | Poster Presentation | AXL targeting with bemcentinb restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through innate immune cell mediated expansion of TCF1+ CD8 T cells | Huiyu Li, BS; Zhida Liu, PhD; Longchao Liu, PhD; Hongyi Zhang; Chuanhui Han, PhD; Luc Girard, Ph.D.; Hyunsil Park; Anli Zhang, PhD; Chunbo Dong; Jianfeng Ye; Austin Rayford, MS; Michael Peyton, Ph.D.; Xiaoguang Li; Kim Avila; Xuezhi Cao; Shuiqing Hu; Esra Akbay, PhD; Luisa M. Solis, MD; Carmen Behrens, MD; Sharia Hernandez-Ruiz; Lu Wei; Ignacio Wistuba, MD; John V. Heymach, MD, PhD; Michael Chisamore, PhD; David Micklem, PhD; Hani Gabra, MD, PhD, FRCP; Gro Gausdal, PhD; James B. Lorens, PhD; Bo Li; Yang-Xin Fu, MD, PhD; John D. Minna, M.D.; Rolf A. Brekken, PhD | Combination Immunotherapies | Checkpoint blockade;Dendritic cell;Immune contexture;Immune suppression;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 603 | Poster Presentation | Targeted STAT3 degradation leads to remodeling of an immunosuppressive tumor microenvironment and subsequent sensitization to immune checkpoint therapy | Joyoti Dey, PhD, MPH; Phillip CC. Liu, PhD; Michele Mayo; Rahul Karnik, PhD; Bin Yang, PhD; Vaishali Dixit, PhD; Jieun Jeong, PhD; Jared Gollob, MD; Chris De Savi, PhD | Combination Immunotherapies | Checkpoint blockade;Gene expression;Immune suppression;Leukemia/Lymphoma;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 604 | Poster Presentation | Combining a novel dual RAF/MEK inhibitor with immunomodulation to promote an anti-tumor response. | Lauren Dong, BS; Hyejin Choi, PhD; Sadna Budhu, PhD; Isabell Schulze; Nezar Mehanna; Neal Rosen; Taha Merghoub, PhD; Jedd D. Wolchok, MD/PhD | Combination Immunotherapies | Checkpoint blockade;Costimulation;Targeted therapy | |
| 605 | Poster Presentation | NHS-IL12 plus Entinostat combination effectively targets anti-PD-1/PD-L1 checkpoint resistant murine tumors harboring MHC Class I and antigen processing machinery deficiency | Christine M. Minnar, PhD; Paul L. Chariou, PhD; Kristin C. Hicks, PhD; Jeffrey Schlom, PhD; Sofia R. Gameiro, PharmD, PhD | Combination Immunotherapies | Antigen presenting cells;Cytokine;Epigenetics;Solid tumors;Targeted therapy;Tumor microenvironment | |
| 606 | Poster Presentation | SAR444245 (THOR-707), an engineered non-alpha IL-2, enhances NK mediated antibody-dependent cellular cytotoxicity | Julie-Ann Gavigan; Nicole V. Acuff; Christen Buetz; Michael Lampa; Chaomei Shi; Yu-an Zhang; Liqing Chen; Kelly Balko; Virna Cortez-Retamozo; Jill Mooney; Carolina Caffaro; Marcos Milla; Joachim Theilhaber; Donald Jackson; Timothy Wagenaar; Giovanni Abbadessa; Donald Shaffer; Xiangming Li | Combination Immunotherapies | Antibody;Cytokine;NK/NKT cell;Solid tumors | |
| 607 | Poster Presentation | Regional delivery of a TLR9 agonist to boost checkpoint inhibitor responsiveness in liver metastases | Chandra C. Ghosh, PhD; Kyle O’Connell, BS; Kara Heatherton, BS; Jason Laporte, MS; Prajna Guha, PhD; Bryan Cox; Steven C. Katz, MD | Combination Immunotherapies | Checkpoint blockade;MDSC;Solid tumors;TLR;Tumor microenvironment | |
| 608 | Poster Presentation | Synergistic effect of the combination of ATG-017, an ERK1/2 inhibitor, and immune checkpoint inhibitor in preclinical cancer models | Bing Hou, Ph.D; Peng Chen; Yun Liu; Min Deng; Jian Wang; Dirk Hoenemann; Kevin Lynch; Jay Mei; Bo Shan | Combination Immunotherapies | Checkpoint blockade;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 609 | Poster Presentation | Combining bintrafusp alfa with abituzumab enhances suppression of the TGF-β signaling pathway | Feng Jiang, PHD; Hong Wang; Tsz-Lun Yeung; Guozhong Qin; Bo Marelli; Hui Huang, Ph.D.; Kin-Ming Lo; Yan Lan, MD | Combination Immunotherapies | Bispecifics;Checkpoint blockade;Cytokine;Tumor microenvironment | |
| 610 | Poster Presentation | Sustainable regression of disseminated solid tumors mediated by in situ combinational treatment with adoptive T cell therapy and oncolytic adenovirus Delta-24-RGDOX | Hong Jiang, PhD; Dong Ho Shin; Sagar s. Sohoni, PhD; Teresa T. Nguyen, PhD; Yanhua Yi; Xuejun Fan, BS; Joy Gumin; Sanjay k. Singh, PHD; Frederick Lang, MD; Candelaria Gomez-Manzano; Juan Fueyo | Combination Immunotherapies | Adoptive immunotherapy;Solid tumors;T cell;Targeted therapy | |
| 611 | Poster Presentation | Exploiting T cells as vehicles of liposomal SHP2i to enhance adoptive cell therapy | Xin Li, MSc; Hólmfridur R. Halldórsdóttir; Sven Weller; Anna Colliander; Ditte Jæhger, PhD; Martin Bak; Gael Clergeaud, PhD; Thomas L. Andresen, PhD | Combination Immunotherapies | Adoptive immunotherapy;Checkpoint blockade;T cell;Targeted therapy | |
| 612 | Poster Presentation | Human ribonucleases act as potential plasma biomarkers for targeted therapy and immunotherapy in hepatocellular carcinoma | Zhengyu Zha; Chenhao Zhou; Dihua Yu; Mien-Chie Hung; Chunxiao Liu, PhD; Ning Ren | Combination Immunotherapies | Biomarkers;Checkpoint blockade;Targeted therapy;Tumor microenvironment | |
| 613 | Poster Presentation | 9-ING-41, a selective small molecule inhibitor of Glycogen Synthase Kinase-3 beta (GSK-3beta), may enhance neuroblastoma immunogenicity | Angela Markovska, MSc; Marianne Boes, PhD; Francis Giles, MD | Combination Immunotherapies | Checkpoint blockade;Metabolism;Pediatric tumors;Solid tumors;T cell;Targeted therapy | |
| 614 | Poster Presentation | Investigating immune mediated mechanisms of PARPi resistance in BRCA1-associated triple negative breast cancer (TNBC) | Anita K. Mehta, PhD; Madeline G. Townsend; Madisson Oliwa; Patrice A. Lee, PhD; Nicholas A. Saccomano, PhD; Filipa Lynce, MD; Geoffrey I. Shapiro, MD, PhD; Elizabeth A. Mittendorf, MD, PhD; Jennifer L. Guerriero, PhD | Combination Immunotherapies | Checkpoint blockade;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy;Tumor microenvironment | |
| 615 | Poster Presentation | Reactivating antitumor immunity in gliomas with osteopontin/integrin blocking peptide | Paulina Pilanc-Kudlek, MSc; Katarzyna Poleszak, PhD; Aleksandra Ellert-Miklaszewska, PhD; Adria-Jaume Roura Canalda, MSc; Salwador Cyranowski, MSc; Julian Swatler, MSc; Bartlomiej Gielniewski, PhD; Bozena Kaminska, Prof. | Combination Immunotherapies | Angiogenesis;Checkpoint blockade;Immune suppression;Monocyte/Macrophage;Myeloid cells;Tumor microenvironment | |
| 616 | Poster Presentation | CD47 blockade modulates immunosuppressive checkpoint molecules and cellular metabolism to sensitize triple-negative breast cancer tumors to immune checkpoint blockade therapy | Elizabeth R. Stirling, MS; Adam Wilson, .; Katherine L. Cook, PhD; Alexandra Thomas, MD; Pierre L. Triozzi; David R. Soto-Pantoja, PhD | Combination Immunotherapies | Biomarkers;Checkpoint blockade;Immune suppression;Metabolism;Solid tumors;Tumor microenvironment | |
| 617 | Poster Presentation | Trastuzumab and Pertuzumab combination therapy activates complement-dependent cytotoxicity and phagocytosis against HER2+ breast cancer | Li-Chung Tsao, PhD; Zachary C. Hartman, PhD | Combination Immunotherapies | Antibody;Coinhibition;Monocyte/Macrophage;Solid tumors;Targeted therapy | |
| 618 | Poster Presentation | Expanding Cancer Immunotherapy by Exploiting Recall Immunity – A New Co-Therapy Option for Checkpoint Inhibitors | Indu Venugopal, PhD; Kathlynn C. Brown; Michael J. McGuire; Anuja Pande | Combination Immunotherapies | Antigen presenting cells;Checkpoint blockade;Solid tumors;T cell;Targeted therapy | |
| 619 | Poster Presentation | Pharmacologic modulation of tumor glycolysis to improve responses to immune checkpoint blockade therapy | Svena Verma, BS; Rachana Maniyar, PhD; Myat K. Ko; Sadna Budhu, PhD; Inna Serganova; Roberta Zappasodi, PhD; Ronald Blasberg; Taha Merghoub, PhD; Jedd D. Wolchok, MD/PhD; Levi M. Mangarin, BS | Combination Immunotherapies | Metabolism | |
| 620 | Poster Presentation | Onco-immunological mechanisms of focal ablation and localized IL-12 immunotherapy | Maura R. Vrabel, B.S.; David A. Zaharoff, PhD; Siena M. Mantooth, BS | Combination Immunotherapies | Immune adjuvant;Solid tumors;Surgery;Targeted therapy | |
| 621 | Poster Presentation | NKG2A and HLA-E define a novel mechanism of resistance to immunotherapy with M. bovis BCG in non-muscle-invasive bladder cancer patients | Amir Horowitz, PhD; Jorge Daza, MD; Y. Alice Wang, PhD; Daniel Ranti; Berengere Salome, PharmD, PhD; Elliot Merritt, PhD; Julie-Ann Cavallo-Fleming, PhD; Everado Hegewisch-Solloa; Emily M. Mace, PhD; Adam M. Farkas, PhD; Sanjana Shroff, PhD; Michelle Tran, MD PhD Candidate; Jingjing Qi, PhD; Manishkumar Patel, PhD; Daniel Geanon; Geoffrey Kelly; Ronaldo de Real; Brian Lee; Seunghee Kim-Schulze, PhD; Tin Htwe Thin, PhD; Monica Garcia-Barros; Kristin G. Beaumont; Ying-Chih Wang; Li Wang, PhD; Dominic LaRoche, PhD; Yong Lee; Robert Sebra; Rachel Brody, MD, PhD; Reza Mehrazin, MD; Jun Zhu, PhD; Anna Tocheva, PhD; Benjamin Hopkins, PhD; Peter Wiklund, MD; Matthew D. Galsky, MD; Nina Bhardwaj, MD, PhD; John P. Sfakianos, MD | Combination Immunotherapies | Checkpoint blockade;Inflammation;NK/NKT cell;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 622 | Poster Presentation | Disrupted oxygen supply and tumor hyper- oxygen consumption contribute independently to prostate cancer immune privilege | Priyamvada Jayaprakash, PhD; Meghan Rice; Krithikaa Rajkumar Bhanu; Brittany Morrow; Joseph R. Marszalek, PhD; Jason P. Gay, PhD; Christopher P. Vellano, PhD; Benjamin R. Cowen, PhD, MBA; Dean J. Welsch, PhD; Michael A. Curran, PhD | Combination Immunotherapies | Checkpoint blockade;Immune suppression;MDSC;Metabolism;Myeloid cells;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 623 | Poster Presentation | Notch Orchestrates A Multifaceted Immune Evasion Program in Hepatocellular Carcinoma | Katherine E. Lindblad, BS; Marina Ruiz de Galarreta, PhD; Romain Donne, PhD; Marina Bárcena-Varela, PhD; Ian Liebling; David Repáraz; Melissa Yao, B.S.; Maxime Dhainaut, PhD; Brian Brown, PhD; Alice O. Kamphorst, PhD; Amaia Lujambio, PhD | Combination Immunotherapies | Checkpoint blockade;T cell;Targeted therapy;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 624 | Poster Presentation | Targeting Type I arginine methyltransferases promotes T cell mediated antitumor immune responses | Leilei Shi, PhD; Andrew Fedoriw; Shane O'Brien; Kimberly Smitheman; Yunfei Wang; Jiakai Hou, Ph.D; Christian Sherk; Satyajit Rajapurkar; Jenny Laraio; Leila Williams; Chunyu Xu; Guangchun Han; Qin Feng; Mark T. Bedford; Linghua Wang, PhD; Olena Barbash; Ryan G. Kruger; Patrick Hwu; Helai P. Mohammad; Weiyi Peng, PhD | Combination Immunotherapies | Checkpoint blockade;Gene expression;Immune suppression;Post-translational modifications;T cell;Tumor evasion;Tumor microenvironment | |
Late-Breaking | ||||||
| 962 | Poster Presentation | Integrative immunomics highlight the immunomodulatory impact of neoadjuvant chemotherapy and immune-based treatments in resected non-small-cell lung cancer | Stephanie T. Schmidt, PhD; Younghee Lee, PhD; Cheuk H. Leung, MS; Lorenzo Federico, PhD; Heather Lin, PhD; Annikka Weissferdt, MD; Apar Pataer, MD, PhD; Hitoshi Dejima, PhD; Alejandro Francisco-Cruz, PhD; Frank Rojas, MD; Luisa M. Solis, MD; Edwin R. Parra, MD, PhD; Monika Pradhan, PhD; Haiping Guo; William N. William, MD; Alexandre Reuben, PhD; Humam Kadara, PhD; Ignacio Wistuba, MD; Jianjun Zhang, MD, PhD; Stephen G. Swisher, MD; Ara A. Vaporciyan, MD; Marcelo V. Negrao, MD; Christopher A. Bristow, PhD; Timothy P. Heffernan, PhD; Chantale Bernatchez, PhD; Jack J. Lee, PhD/DDS; John V. Heymach, MD, PhD; Boris Sepesi, MD; Don L. Gibbons, MD, PhD; Cara Haymaker, PhD; Tina Cascone, MD, PhD; | Combination Immunotherapies | Bioinformatics;Checkpoint blockade;Chemotherapy;Tumor microenvironment | |
Presented By:
